β¨ Medicines Consent Notices
30 JUNE 2011 NEW ZEALAND GAZETTE, No. 90 2545
Product:
Sinutab PE Phenylephrine Sinus, Allergy & Pain Relief
Active Ingredients:
Chlorphenamine maleate 2mg
Paracetamol 500mg
Phenylephrine hydrochloride 5mg equivalent to phenylephrine 4.1mg
Dosage Form:
Tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturer:
Pfizer Laboratories (Pty) Limited, Cape Town, South Africa
Product:
Sudafed PE Phenylephrine Sinus + Allergy & Pain Relief
Active Ingredients:
Chlorphenamine maleate 2mg
Paracetamol 500mg
Phenylephrine hydrochloride 5mg equivalent to phenylephrine 4.1mg
Dosage Form:
Tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturers:
Pfizer Laboratories (Pty) Limited, Cape Town, South Africa
Janssen-Cilag, Val de Reuil, France
Product:
Sudafed PE Phenylephrine Sinus + Pain Relief
Active Ingredients:
Paracetamol 500mg
Phenylephrine hydrochloride 5mg equivalent to phenylephrine 4.1mg
Dosage Form:
Tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturers:
Pfizer Laboratories (Pty) Limited, Cape Town, South Africa
Janssen-Cilag, Val de Reuil, France
Product:
Sudafed PE Phenylephrine Sinus Day + Night Relief (Combination Product)
Day Tablet
Active Ingredients:
Paracetamol 500mg
Phenylephrine hydrochloride 5mg
Dosage Form:
Tablet
Night Tablet
Active Ingredients:
Chlorphenamine maleate 2mg
Paracetamol 500mg
Phenylephrine hydrochloride 5mg
Dosage Form:
Tablet
New Zealand Sponsor:
Johnson & Johnson (New Zealand) Limited
Manufacturers:
Pfizer Laboratories (Pty) Limited, Cape Town, South Africa
Janssen-Cilag, Val de Reuil, France
Dated this 22nd day of June 2011.
MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4300
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Arrow - Losartan Potassium
Active Ingredient:
Losartan potassium 25mg
Dosage Form:
Tablet
New Zealand Sponsor:
Ipca Pharma (NZ) Pty Limited
Manufacturer:
Ipca Laboratories Limited, Dadra and Nagar Haveli, India
Product:
Arrow - Losartan Potassium
Active Ingredient:
Losartan potassium 50mg
Dosage Form:
Tablet
New Zealand Sponsor:
Ipca Pharma (NZ) Pty Limited
Manufacturer:
Ipca Laboratories Limited, Dadra and Nagar Haveli, India
Product:
Arrow - Losartan Potassium
Active Ingredient:
Losartan potassium 100mg
Dosage Form:
Tablet
New Zealand Sponsor:
Ipca Pharma (NZ) Pty Limited
Manufacturer:
Ipca Laboratories Limited, Dadra and Nagar Haveli, India
Next Page →
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare22 June 2011
Medicines Act, New Medicines, Consent, Distribution
- MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social WelfareMedicines Act, New Medicines, Consent, Distribution
NZ Gazette 2011, No 90